Matrix metalloproteinase (collagenase isoforms) (MMPs)

The collagenolytic isoforms of matrix metalloproteinases (MMPs), primarily comprising MMP-1, MMP-8, and MMP-13, are a specialized group of zinc-dependent endopeptidases characterized by their unique ability to cleave the triple-helical structure of fibrillar collagens (Types I, II, and III). These enzymes are essential for physiological processes such as tissue remodeling, wound healing, and bone development, where they initiate the degradation of the structural scaffold of the extracellular matrix. In pathological states, their overactivity is a major driver of tissue destruction; for instance, MMP-1 and MMP-13 are highly upregulated in rheumatoid arthritis and osteoarthritis, leading to irreversible cartilage loss, while their role in cancer facilitates tumor invasion and metastasis by breaking down physical barriers. Therapeutic targeting of these isoforms has historically focused on small-molecule inhibitors, such as marimastat and batimastat, which utilize hydroxamate groups to chelate the catalytic zinc ion. However, most broad-spectrum inhibitors failed in clinical trials due to the development of a dose-limiting musculoskeletal syndrome (MSS) and a lack of selectivity between beneficial and detrimental MMPs. Currently, low-dose doxycycline (Periostat) is the only FDA-approved MMP inhibitor, specifically used for its non-antimicrobial collagenase-inhibitory properties in periodontitis. Modern drug discovery efforts are shifting toward highly selective monoclonal antibodies and allosteric inhibitors to bypass the toxicity associated with broad-spectrum zinc-binding ligands.

Other names

CollagenasesInterstitial collagenasesMatrix metalloproteinase-1 (Collagenase-1)Matrix metalloproteinase-8 (Collagenase-2)Matrix metalloproteinase-13 (Collagenase-3)Fibrillar collagenases

Competitive inhibition of enzyme activity by chelating the catalytic zinc ion (Zn2+) in the active site.